Amyloid precursor protein interacts with the mitochondrial phosphatase PGAM5 and regulates mitochondrial respiration

This study reveals that Amyloid Precursor Protein (APP) directly interacts with the mitochondrial phosphatase PGAM5 at mitochondria-ER contact sites to stabilize the PGAM5-Keap1-Nrf2 signaling complex, thereby regulating the expression of respiratory genes and maintaining mitochondrial respiration.

The Gist

The Big Picture: A Broken Power Plant in the Brain

Imagine your brain is a bustling city, and the mitochondria are the power plants that keep the lights on and the trains running. In Alzheimer's disease, these power plants start to fail, leading to a city-wide blackout (memory loss and cognitive decline).

For a long time, scientists knew that a protein called APP (Amyloid Precursor Protein) was involved in Alzheimer's, mostly because it gets chopped up to form the sticky "plaques" that clog the brain. But they didn't fully understand what APP was doing before it got chopped up, especially inside the power plants.

This new study acts like a detective story, revealing that APP has a secret job: it's the foreman that keeps the power plant running efficiently.

---

The Characters

1. APP (The Foreman): A protein that usually hangs out on the cell surface but also visits the mitochondria.
2. PGAM5 (The Anchor): A protein sitting on the outside of the mitochondria. Think of it as a heavy-duty docking station.
3. Keap1 (The Leash): A protein that acts like a leash, tying another character down.
4. Nrf2 (The Spark Plug): A master regulator that tells the cell to turn on its "antioxidant generators" and repair the power plant.
5. The MERCS (The Busy Intersection): A special meeting spot where the mitochondria and the ER (another cell part) touch. This is where the drama happens.

---

The Story: How the Team Works

1. The Secret Handshake

The researchers discovered that APP and PGAM5 hold hands. They found this happening naturally in mouse brains. Even better, they found that both of them hang out at the MERCS (the busy intersection). It's like finding the Foreman and the Anchor working together right at the entrance of the power plant.

2. The Tug-of-War

Here is the tricky part. Normally, Keap1 (the Leash) grabs Nrf2 (the Spark Plug) and ties it to PGAM5 (the Anchor).

• The Problem: When Nrf2 is tied down, it can't go to the "control room" (the nucleus) to give orders. The power plant stays in "sleep mode" and doesn't produce enough energy or defense systems.

The Discovery: The study shows that APP comes along and pushes Keap1 out of the way.

• Think of it like this: APP is a strong construction worker who walks up to the Anchor (PGAM5), pushes the Leash (Keap1) aside, and frees the Spark Plug (Nrf2).
• Once free, Nrf2 runs to the control room and shouts, "Turn on the generators! Make more energy! Fix the rust!"

3. What Happens When APP is Missing?

The researchers looked at mice that were missing the APP "Foreman" (APP Knockout mice).

• The Leash stays tight: Without APP to push it aside, Keap1 keeps Nrf2 tied to the Anchor.
• The Spark Plug is silent: Nrf2 can't get to the control room.
• The Power Plant fails: The genes that make the power plant efficient (specifically Hmox1 and Nqo1) are never turned on.

4. The Result: A Dimmer Switch

When they tested the mitochondria from the APP-missing mice, they found the power plants were struggling.

• They could still run on some fuels (like succinate), but when they tried to run on the main fuels (pyruvate and glutamate), they sputtered and failed.
• It's like a car that can idle in neutral but stalls the moment you try to drive up a hill. The engine (Complex I) is weak, and the whole system is less efficient.

---

Why This Matters

This study changes how we view Alzheimer's. It suggests that the problem isn't just the sticky plaques clogging the brain later in the disease. The problem might start much earlier, when the "Foreman" (APP) is missing or broken, causing the power plants to lose their ability to regulate themselves.

The Takeaway:
APP isn't just a villain that creates plaques; it's actually a hero that helps keep our brain's energy factories running smoothly. By interacting with PGAM5, it frees up the "Spark Plug" (Nrf2) to keep the brain healthy, protected from stress, and full of energy. If we can understand how to keep this interaction working, we might find new ways to prevent the energy failure that leads to Alzheimer's.

Technical Summary

1. Problem Statement

Mitochondrial dysfunction is a hallmark of Alzheimer's disease (AD), characterized by oxidative stress, reduced ATP levels, and impaired brain metabolism. The Amyloid Precursor Protein (APP), the parent protein of amyloid-beta (Aβ) plaques, is known to partially localize to mitochondria and mitochondria-ER contact sites (MERCS). While APP is established to influence mitochondrial mass, bioenergetics, and mitophagy, the specific molecular mechanisms by which APP regulates mitochondrial respiration remain undefined. Previous proteomic screens suggested a potential interaction between APP and the mitochondrial phosphatase PGAM5, but this link and its functional consequences had not been experimentally validated.

2. Methodology

The study employed a multi-faceted approach combining molecular biology, biochemistry, and physiological assays:

• Endogenous Interaction Validation: Co-immunoprecipitation (Co-IP) was performed on brain extracts from wild-type (WT) and PGAM5 knockout (KO) mice to confirm physical interaction.
• Subcellular Localization: Subcellular fractionation of mouse brains was used to isolate mitochondria, endoplasmic reticulum (ER), and MERCS to determine the co-localization of APP and PGAM5.
• In Vitro Binding Assays:
  • Recombinant soluble APP (sAPPα) and truncated PGAM5 constructs (PGAM5Δ54 and PGAM5Δ90) were used in pull-down assays to map interaction domains.
  • Isothermal Titration Calorimetry (ITC) was utilized to measure binding affinity ($K_d$) and stoichiometry between sAPPα and PGAM5.
• Gene Expression Analysis: Primary astrocytes from WT and APP KO mice were cultured. Quantitative PCR (qPCR) was used to measure transcript levels of Nrf2 target genes (Hmox1, Nqo1, Gclc, Gclm, Txnrd1).
• Mitochondrial Respiration Assays: Freshly isolated mitochondria from WT and APP KO mouse brains were subjected to high-resolution respirometry to measure substrate-specific respiration (pyruvate/malate, glutamate/malate, succinate).
• Enzymatic Activity: Complex I activity and total NADH oxidase activity were measured to assess Electron Transport Chain (ETC) function.

3. Key Contributions

• Discovery of a Novel Interaction: The study identifies and validates a direct physical interaction between APP and PGAM5, a mitochondrial phosphatase.
• Mapping the Binding Interface: The authors pinpointed that the interaction occurs between the linker region of APP (specifically the Extension and Acidic domains) and the N-terminal region of PGAM5 (containing the Keap1-binding domain and multimerization motif).
• Mechanistic Insight into Nrf2 Signaling: The paper proposes a novel mechanism where APP competes with Keap1 for binding to PGAM5, thereby regulating the Keap1-Nrf2 signaling pathway at the mitochondria.
• Functional Link to Bioenergetics: The study establishes that APP is essential for maintaining NADH-linked mitochondrial respiration and Complex I function in the brain.

4. Key Results

• Endogenous Interaction and Localization:
  • APP and PGAM5 co-immunoprecipitate in WT mouse brain tissue but not in PGAM5 KO tissue.
  • Both proteins are present at MERCS (Mitochondria-ER Contact Sites), a site of APP processing, in addition to their respective primary compartments (ER for APP, Mitochondria for PGAM5).
• Binding Specificity:
  • Pull-down assays revealed that APP binds to PGAM5Δ54 (lacking the transmembrane domain) but not PGAM5Δ90 (lacking the Keap1-binding domain), indicating the Keap1-binding domain (KBD) of PGAM5 is critical.
  • ITC analysis showed a dissociation constant ($K_d$) of 3.45 µM with a binding stoichiometry ($N$) of 0.114, consistent with a model where an APP dimer interacts with a PGAM5 dodecamer.
  • The APP Extension Domain (ExD) and Acidic Domain (AcD) were identified as the primary binding sites on APP.
• Impact on Nrf2 Signaling:
  • In APP KO astrocytes, the mRNA expression of key Nrf2 target genes Hmox1 (Heme oxygenase-1) and Nqo1 (NADH:quinone oxidoreductase 1) was significantly downregulated compared to WT.
  • Other Nrf2 targets (Gclc, Gclm, Txnrd1) showed no significant change, suggesting a selective effect.
• Mitochondrial Dysfunction in APP KO:
  • Mitochondria from APP KO mice exhibited impaired respiration specifically when fueled by pyruvate and glutamate (NADH-linked substrates, Complex I dependent).
  • Succinate-mediated respiration (Complex II dependent) remained intact, indicating the defect is upstream of or at Complex I.
  • NADH oxidase activity was significantly decreased in APP KO mitochondria, with a non-significant downward trend in Complex I enzymatic activity.

5. Significance and Proposed Model

The study proposes a mechanistic model explaining how APP supports mitochondrial health:

1. In Wild-Type (WT) Conditions: APP localizes to MERCS and binds to the Keap1-binding domain of PGAM5. This interaction likely competes with or displaces Keap1, preventing the tethering of Nrf2 to the mitochondrial outer membrane. Consequently, Nrf2 is released, accumulates in the cytoplasm, translocates to the nucleus, and upregulates antioxidant and respiratory genes (specifically Hmox1 and Nqo1).
2. In APP Deficiency (KO): Without APP, PGAM5 retains Keap1-bound Nrf2 at the mitochondria. This prevents Nrf2 nuclear translocation, leading to reduced transcription of genes essential for redox homeostasis and Complex I function.
3. Pathophysiological Implication: The loss of normal APP function (distinct from Aβ toxicity) leads to a bioenergetic deficit characterized by impaired NADH-linked respiration and increased oxidative stress. This suggests that mitochondrial dysfunction in Alzheimer's disease may arise, at least in part, from the loss of APP's physiological role in regulating the PGAM5-Keap1-Nrf2 axis.

Conclusion: This paper redefines APP not just as a source of toxic Aβ, but as a critical regulator of mitochondrial respiration via its interaction with PGAM5 and modulation of the Nrf2 antioxidant pathway. These findings offer a new therapeutic angle for AD focused on preserving APP-PGAM5 interactions to maintain mitochondrial bioenergetics.